Insider Buying: Septerna, Inc. (NASDAQ:SEPN) CFO Purchases 3,718 Shares of Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie purchased 3,718 shares of Septerna stock in a transaction dated Thursday, February 27th. The stock was bought at an average price of $5.85 per share, for a total transaction of $21,750.30. Following the completion of the purchase, the chief financial officer now owns 40,000 shares in the company, valued at $234,000. This represents a 10.25 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Septerna Stock Performance

Shares of SEPN opened at $5.80 on Friday. The stock’s 50-day moving average is $16.43. Septerna, Inc. has a 12 month low of $4.17 and a 12 month high of $28.99.

Institutional Trading of Septerna

Institutional investors have recently bought and sold shares of the company. RA Capital Management L.P. acquired a new position in shares of Septerna during the fourth quarter valued at about $160,205,000. TRV GP V LLC bought a new stake in shares of Septerna during the fourth quarter valued at approximately $142,337,000. TRV GP VI LLC acquired a new position in shares of Septerna during the fourth quarter worth approximately $72,191,000. Samsara BioCapital LLC bought a new position in shares of Septerna in the 4th quarter worth $63,399,000. Finally, Driehaus Capital Management LLC acquired a new stake in Septerna in the 4th quarter valued at $59,301,000.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on SEPN. Cantor Fitzgerald restated an “overweight” rating and issued a $50.00 target price on shares of Septerna in a research report on Tuesday, February 11th. Wells Fargo & Company downgraded Septerna from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $43.00 to $14.00 in a report on Tuesday, February 18th. JPMorgan Chase & Co. assumed coverage on Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price for the company. Finally, TD Cowen assumed coverage on Septerna in a report on Tuesday, November 19th. They set a “buy” rating on the stock.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.